Overview
GSK is seeking a highly skilled Executive Medical Director, Clinical Development, Advanced Pipeline Unit (APU) Respiratory to provide clinical and scientific leadership for potential new, established and emerging indications for assets in clinical development with a strong focus on Interstitial Lung Diseases (ILD) including Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis (PPF) and autoimmune-associated ILDs including connective tissue disease Associated ILD (CTD-ILD). You will work with project teams to plan and ensure delivery of clinical research and development activities and establish efficient collaboration throughout all stages of development. You will report to the Vice President, Clinical Research Head in Respiratory. This role is pivotal in driving GSK’s mission to deliver transformative medicines to patients, ensuring clinical excellence, regulatory compliance, and operational efficiency. The successful candidate will not only deliver results but also inspire and empower teams to achieve exceptional outcomes.
About RIIRU: The Respiratory, Immunology and Inflammation Research Unit (RIIRU) was formed in 2024 to identify and advance novel molecular targets with genetic associations to disease based on the foundational observation that targets with human genetic evidence supporting their causal role in the intended indication improves clinical success by two-fold. The remit of RIIRU is to identify novel targets based on human genetics, develop assets for clinical studies, and perform trials through to submission for approvals. This goal is enabled through strategic external (e.g., Flagship Pioneering, Vesalius, Muna Therapeutics and others) and GSK-internal partnerships (Research Technologies).
#J-18808-Ljbffr